Europe Tissue Engineering Market Size and Competitive Analysis by 2027

The Europe Tissue engineering market is expected to reach US$ 7,368.93 million by 2027 from US$ 2,798.86 million in 2019; it is estimated to grow at a CAGR of 13.2% from 2020 to 2027.

The key factors driving the market growth are the increasing incidences of chronic diseases, road accidents and trauma injuries and technological advancement in 3D tissue engineering. However, high costs associated to Tissue engineering process is the major factor hindering the Tissue engineering market growth in Europe.

Tissue engineering is a procedure used as a blend of material methods and cellular activities. This approach explores the physicochemical and biochemical conditions to replace the biological tissues and strengthen them. It is an innovative technology that works either in isolation or in conjunction with the scaffolds, stem cells, regenerative medicine and growth factors or negotiators. The process utilizes molecular and cellular processes in combination with the principles of material engineering to surgically repair and restore tissue.

The rising incidence of chronic diseases as well as number of trauma injuries and road accidents are prime factors contributing to the growth of the market for advanced treatment procedures, such as tissue engineering. For instance, prevalence of diabetes is growing all across the European region among all the age groups. As per WHO’s statistics around 60 million people are suffering from diabetes in Europe region. Similarly, morbidity and mortality due to cancer is also rising in Europe, about 3.7 million new cancer cases and about 1.9 million deaths are reported each year due to various types of cancer. Tissue engineering provide alternative option to surgical reconstruction and transplantation in order to repair damaged tissues in these chronic diseases. The Europe tissue engineering market is primarily driven by a continued demand for successful regenerative therapies to treat rising cases of diabetes, obesity, and other chronic disorders caused by lifestyle changes; growing elderly population base; and increasing number of trauma injury cases.

Stryker Corporation, Organogenesis Inc., Cook Biotech Inc., Integra Life Sciences Corporation are among the major companies in Tissue engineering technology and material. In the Europe, due to an increasing number of COVID 19 infected patients, healthcare professionals and leading organizations are distracting the flow of healthcare resources from research & development to primary care, which is slowing down the process of innovation. Further, the COVID-19 pandemic spread is also hindering the conduct of clinical trials and drug development, and operations of diagnostic industry in the Europe. For instance, Stryker Corporation, a well-known player in the tissue engineering industry, has diverted operations to manufacture COVID-19 diagnostics and PPE kits. Moreover, according to a recent survey by Medscape in July 2020, substantial disruption has been witnessed in routine research activities that includes tissue engineering and regenerative medicines as a result of the COVID-19 pandemic. The rapid increase in the number of the infected patients in the Italy and Spain is likely to result in the slowdown of the market growth in the near future.

Germany Tissue engineering Market, Revenue and Forecast to 2027 (US$ Mn)

EUROPE TISSUE ENGINEERING MARKET SEGMENTATION

EUROPE TISSUE ENGINEERING MARKET SEGMENTATION

By Material Type

• Biologically Derived Material
• Synthetic Material
• Others

By Application

• Orthopedic, Musculoskeletal and Spine
• Skin

• Cardiology and Vascular
• Neurology
• Others

By Country

• Germany
• France
• Italy
• U.k.
• Spain

Company Profiles

• Stryker Corporation
• Organogenesis Inc.        
• Cook Biotech Inc.
• Integra Life Sciences Corporation
• Acelity L.P.Inc     
• Allergan Plc.       
• Medtronic
• Zimmer Biomet
• Baxter International Inc.
• DePuy Synthes (Johnson & Johnson Services, Inc.)

Europe Tissue Engineering Report Scope